Skip to main content
    Q

    Quest Diagnostics Incorporated (DGX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $262.26
    +2.66 (+1.02%)

    Market Cap: $28.56B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Quest Diagnostics Incorporated (DGX) Earnings: Report Dates and Results

    Updated Oct 22, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Quest Diagnostics (DGX) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Quest Diagnostics reported EPS of $3.00, above the $2.85 estimate. It beat the EPS estimate in each of the last 31 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +5.19%
    Streak
    31 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.71
    Range$2.56 - $2.88
    17 analysts
    Revenue Consensus
    $3.07B
    Range$2.90B - $3.22B
    16 analysts
    Reports Apr 19, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.70
    Range$2.59 - $2.84
    10 analysts
    EPS Estimate DriftChange to current
    90d ago$2.76-2.4%
    60d ago$2.77-2.7%
    30d ago$2.77-2.7%
    7d ago$2.76-2.4%
    Current$2.70
    Revenue Consensus
    $3.03B
    Range$3.00B - $3.08B
    7 analysts

    Next Report

    DGX has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 12.0% above the $2.42 reported for the quarter ended Dec 31, 2025.

    DGX Earnings Call

    The latest DGX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, DGX beat 37, missed 2 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.10B, up 9.9% from $2.82B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.00$2.85$2.82 - $2.94+5.26%Beat+15.4%141 up, 0 downOct 22, 2026$3.10B
    Jun 30, 2026$3.12$2.81$2.75 - $2.91+11.03%Beat+19.1%152 up, 10 downJul 23, 2026$3.04B
    Mar 31, 2026$2.50$2.37$2.25 - $2.47+5.49%Beat+13.1%145 up, 4 downApr 21, 2026$2.90B
    Dec 31, 2025$2.42$2.36$2.28 - $2.41+2.54%Beat+8.5%142 up, 0 downFeb 10, 2026$2.81B
    Sep 30, 2025$2.60$2.50$2.46 - $2.57+4.00%Beat+13.0%152 up, 3 downOct 21, 2025$2.82B
    Jun 30, 2025$2.62$2.57$2.54 - $2.69+1.95%Beat+11.5%149 up, 4 downJul 22, 2025$2.76B
    Mar 31, 2025$2.21$2.15$2.08 - $2.24+2.79%Beat+8.3%140 up, 9 downApr 22, 2025$2.65B
    Dec 31, 2024$2.23$2.18$2.13 - $2.22+2.29%Beat+3.7%150 up, 2 downJan 30, 2025$2.62B
    Sep 30, 2024$2.30$2.26$2.22 - $2.32+1.77%Beat+3.6%160 up, 5 downOct 22, 2024$2.49B
    Jun 30, 2024$2.35$2.33$2.26 - $2.39+0.86%Beat+2.2%152 up, 0 downJul 23, 2024$2.40B
    Mar 31, 2024$2.04$1.86$1.82 - $1.90+9.68%Beat0.0%162 up, 0 downApr 23, 2024$2.37B
    Dec 31, 2023$2.15$2.11$1.83 - $2.18+1.90%Beat+8.6%151 up, 0 downFeb 1, 2024$2.29B
    Sep 30, 2023$2.22$2.19$2.09 - $2.25+1.37%Beat-5.9%150 up, 1 downOct 24, 2023$2.29B
    Jun 30, 2023$2.30$2.26$2.11 - $2.36+1.77%Beat-2.5%163 up, 1 downJul 26, 2023$2.34B
    Mar 31, 2023$2.04$1.97$1.92 - $2.07+3.55%Beat-36.6%140 up, 1 downApr 27, 2023$2.33B
    Dec 31, 2022$1.98$1.90$1.85 - $1.96+4.21%Beat-40.5%154 up, 0 downFeb 2, 2023$2.33B
    Sep 30, 2022$2.36$2.19$2.06 - $2.34+7.76%Beat-40.4%143 up, 1 downOct 20, 2022$2.49B
    Jun 30, 2022$2.36$2.27$2.13 - $2.71+3.96%Beat-25.8%144 up, 0 downJul 21, 2022$2.45B
    Mar 31, 2022$3.22$3.00$2.62 - $3.60+7.33%Beat-14.4%142 up, 2 downApr 21, 2022$2.61B
    Dec 31, 2021$3.33$3.21$2.75 - $3.52+3.74%Beat-25.7%156 up, 1 downFeb 3, 2022$2.74B
    Sep 30, 2021$3.96$3.06$2.07 - $3.76+29.41%Beat-8.1%15N/AOct 21, 2021$2.77B
    Jun 30, 2021$3.18$2.86$2.61 - $2.99+11.19%Beat+123.9%14N/AJul 22, 2021$2.55B
    Mar 31, 2021$3.76$3.73$3.41 - $4.09+0.80%Beat+300.0%15N/AApr 22, 2021$2.72B
    Dec 31, 2020$4.48$4.24$3.75 - $4.65+5.66%Beat+168.3%14N/AFeb 4, 2021$3.00B
    Sep 30, 2020$4.31$3.73$3.14 - $4.25+15.55%Beat+144.9%15N/AOct 22, 2020$2.79B
    Jun 30, 2020$1.42$1.25N/A+13.60%Beat-17.9%7N/AJul 23, 2020$1.83B
    Mar 31, 2020$0.94$0.88$0.31 - $1.49+6.82%Beat-32.9%13N/AApr 22, 2020$1.82B
    Dec 31, 2019$1.67$1.60$1.58 - $1.65+4.38%Beat+22.8%16N/AJan 30, 2020$1.93B
    Sep 30, 2019$1.76$1.71$1.65 - $1.79+2.92%Beat+4.8%16N/AOct 22, 2019$1.96B
    Jun 30, 2019$1.73$1.68$1.62 - $1.73+2.98%Beat-1.1%18N/AJul 23, 2019$1.95B
    Mar 31, 2019$1.40$1.38$1.30 - $1.39+1.45%Beat-7.9%18N/AApr 23, 2019$1.89B
    Dec 31, 2018$1.36$1.37$1.29 - $1.40-0.73%Miss-2.9%17N/AFeb 14, 2019$1.84B
    Sep 30, 2018$1.68$1.68$1.63 - $1.740.00%In line+20.9%17N/AOct 23, 2018$1.89B
    Jun 30, 2018$1.75$1.76$1.70 - $1.78-0.57%Miss+12.9%16N/AJul 24, 2018$1.92B
    Mar 31, 2018$1.52$1.50$1.41 - $1.58+1.33%Beat+14.3%17N/AApr 19, 2018$1.88B
    Dec 31, 2017$1.40$1.37$1.34 - $1.55+2.19%Beat+6.9%18N/AFeb 1, 2018$1.86B
    Sep 30, 2017$1.39$1.36$1.28 - $1.45+2.21%Beat+1.5%17N/AOct 19, 2017$1.86B
    Jun 30, 2017$1.55$1.42$1.38 - $1.51+9.15%Beat+15.7%20N/AJul 25, 2017$1.86B
    Mar 31, 2017$1.33$1.18N/A+12.71%Beat+18.7%N/AN/AApr 20, 2017$1.82B
    Dec 31, 2016$1.31$1.27N/A+3.15%Beat+10.1%N/AN/AJan 26, 2017$1.56B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $9.85, up 10.4% from the year before. It was $5.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$9.85+10.4%
    Dec 31, 2024$8.92+2.4%
    Dec 31, 2023$8.71-12.2%
    Dec 31, 2022$9.92-30.3%
    Dec 31, 2021$14.23+27.6%
    Dec 31, 2020$11.15+70.0%
    Dec 31, 2019$6.56+4.0%
    Dec 31, 2018$6.31+11.3%
    Dec 31, 2017$5.67+10.3%
    Dec 31, 2016$5.14N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,26417
    2026Q2Jun 30, 20267,47915
    2026Q1Mar 31, 20267,63417
    2025Q4Dec 31, 20258,42215
    2025Q3Sep 30, 20256,76517
    2025Q2Jun 30, 20256,79917
    2025Q1Mar 31, 20257,23816
    2024Q4Dec 31, 20247,69615

    2026Q3 Earnings Call

    Opening remarks

    Dominique Joshi Vice President of Investor Relations Thank you, and good morning. I am joined by Jim Davis, our Chairman, Chief Executive Officer, and President, and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and we will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long-term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth, are compound annual growth rates. Now here is Jim.

    Jim Davis Chairman, CEO, and President Thanks, Dominique, and welcome everyone to this morning's call. I am excited to discuss our strong performance in the third quarter and how our strategy to connect people and providers to innovative testing and actionable insights is illuminating paths for better health and generating shareholder value. We grew revenues 10% and adjusted earnings per share over 15% in the quarter on continued strength across our physician, hospital, and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population, as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are again raising our guidance for revenues and earnings per share for the full year. Now I'll provide more detail on how we executed our strategy across our key customer channels and operations during the quarter. Quest operates at the center of healthcare. We deliver solutions that make testing simpler and smarter for our core clinical customers, physicians, and hospitals, as well as for customers in the higher-growth areas of consumer health, life sciences, and data analytics. In the physician channel, we delivered high single-digit revenue growth in the third quarter on strong commercial execution and broad demand across our test portfolio. We also continued to grow in geographies where we've expanded our access in recent years through health plan collaborations and outreach acquisitions. We are excited about our collaborations with Fresenius Medical Care and opportunities to serve new customers based on our growing kidney diagnostics expertise.

    Frequently Asked Questions About DGX

    When is Quest Diagnostics's next earnings date?

    Quest Diagnostics's next earnings report is expected for Feb 8, 2027.

    Did DGX beat earnings estimates last quarter?

    Yes. Quest Diagnostics reported EPS of $3.00 for the quarter ended Sep 30, 2026, above the $2.85 estimate, a 5.26% surprise.

    What EPS do analysts expect from DGX next quarter?

    The consensus EPS estimate for Quest Diagnostics for the quarter ending Dec 31, 2026 is $2.71 from 17 analysts, with estimates from $2.56 to $2.88.

    How often does DGX beat earnings estimates?

    Quest Diagnostics beat the EPS estimate in each of the last 31 quarters, with an average surprise of +5.74%.